LabCorp’s Covance Drug Development segment is set to acquire Envigo’s nonclinical research services business for $485m – while Envigo will purchase Covance’s research products business.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
Taconic Biosciences’ new solution enables researchers to generate and maintain mice with custom microbiome profiles, alterations to which can significantly affect drug efficacy.
Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.
Circuit Clinical partners with the University at Buffalo’s genomics and biorepository program to add personalized medicine capabilities to its service offering lineup.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
Catalent Pharma invests $5m in drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
Metrion Biosciences looks to partner and move its lead candidate into clinical trials later this year fueled by a funding round which will also see its drug discovery services expand throughout 2019.
Horizon Discovery is working with St George’s University Hospital and EMQN to develop reference material for non-invasive prenatal testing, which is being increasingly adopted in the UK and abroad.
Sinclair Research and Turner Scientific sign an exclusive partnership through which the CROs will offer ototoxicity testing services – and improve regulatory guidance regarding the ears to protect patients, says company executive.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.
